PL3010506T3 - Pridopidyna w leczeniu choroby huntingtona - Google Patents

Pridopidyna w leczeniu choroby huntingtona

Info

Publication number: PL3010506T3
Authority: PL; Poland
Prior art keywords: pridopidine; disease; treating huntington; huntington; treating
Prior art date: 2013-06-21

Application number

PL14813621T

Other languages

English (en)

Inventor

Merav Bassan

Eli Eyal

Esther Lukasiewicz Hagai

Anna Kristina Sveinsdotter Teige Wickenberg

Original Assignee

Prilenia Neurotherapeutics Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-21

Filing date

2014-06-19

Publication date

2021-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3010506(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-19 Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.

2021-11-02 Publication of PL3010506T3 publication Critical patent/PL3010506T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL14813621T 2013-06-21 2014-06-19 Pridopidyna w leczeniu choroby huntingtona PL3010506T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361837928P	2013-06-21	2013-06-21
US201361877832P	2013-09-13	2013-09-13
PCT/US2014/043204 WO2014205229A1 (en)	2013-06-21	2014-06-19	Use of high dose pridopidine for treating huntington's disease
EP14813621.1A EP3010506B1 (en)	2013-06-21	2014-06-19	Pridopidine in treating huntington's disease

Publications (1)

Publication Number	Publication Date
PL3010506T3 true PL3010506T3 (pl)	2021-11-02

Family

ID=52105289

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14813621T PL3010506T3 (pl)	2013-06-21	2014-06-19	Pridopidyna w leczeniu choroby huntingtona

Country Status (24)

Country	Link
US (1)	US10322119B2 (pl)
EP (1)	EP3010506B1 (pl)
JP (1)	JP2016523862A (pl)
KR (1)	KR102316933B1 (pl)
CN (1)	CN105592848A (pl)
AU (1)	AU2014281414A1 (pl)
BR (1)	BR112015029918A2 (pl)
CA (1)	CA2913781C (pl)
CL (1)	CL2015003690A1 (pl)
DK (1)	DK3010506T3 (pl)
EA (1)	EA201690069A1 (pl)
ES (1)	ES2879631T3 (pl)
HK (1)	HK1221646A1 (pl)
HU (1)	HUE054783T2 (pl)
IL (1)	IL242804B (pl)
MX (1)	MX384234B (pl)
PE (2)	PE20160195A1 (pl)
PH (1)	PH12015502691A1 (pl)
PL (1)	PL3010506T3 (pl)
SG (1)	SG11201509729YA (pl)
TW (1)	TW201529069A (pl)
UA (1)	UA122999C2 (pl)
UY (1)	UY35624A (pl)
WO (1)	WO2014205229A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
NZ608120A (en)	2010-09-03	2014-12-24	Ivax Int Gmbh	Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en)	2011-12-08	2015-04-21	IVAX International GmbH	Hydrobromide salt of pridopidine
US11090297B2 (en)	2013-06-21	2021-08-17	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating huntington's disease
PE20161220A1 (es) *	2014-01-22	2016-11-23	Teva Pharmaceuticals Int Gmbh	Formulaciones de pridopidina de liberacion modificada
TW201613859A (en)	2014-06-30	2016-04-16	Teva Pharma	Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en)	2014-12-22	2018-09-19	Teva Pharmaceuticals International GmbH	L-tartrate salt of pridopidine
US11471449B2 (en)	2015-02-25	2022-10-18	Prilenia Neurotherapeutics Ltd.	Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
PL3261721T3 (pl) *	2015-02-25	2022-12-27	Prilenia Neurotherapeutics Ltd.	Stososowanie pridopidyny w celu poprawy pamięci
AR105434A1 (es)	2015-07-22	2017-10-04	Teva Pharmaceuticals Int Gmbh	Proceso para preparar pridopidina
US20170020854A1 (en) *	2015-07-22	2017-01-26	Teva Pharmaceuticals International Gmbh	Pridopidine base formulations and their use
WO2017147366A1 (en)	2016-02-24	2017-08-31	Teva Pharmaceuticals International Gmbh	Treatment of neurodegenerative eye disease using pridopidine
PT3504187T (pt)	2016-08-24	2025-05-09	Prilenia Neurotherapeutics Ltd	Utilização da pridopidina no tratamento do declínio funcional
DK3503890T3 (da) *	2016-08-24	2025-01-27	Prilenia Neurotherapeutics Ltd	Anvendelse af pridopidin til behandling af dystonier
CN109952100A (zh)	2016-09-15	2019-06-28	普瑞尼亚医疗发展有限公司	普利多匹定用于治疗焦虑和抑郁的用途
US12102627B2 (en)	2016-09-16	2024-10-01	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for treating rett syndrome
PL3512506T3 (pl)	2016-09-16	2022-05-30	Prilenia Neurotherapeutics Ltd.	Zastosowanie pridopidyny w leczeniu zespołu retta
IL268125B2 (en)	2017-01-20	2023-04-01	Prilenia Neurotherapeutics Ltd	Pridopidine for the treatment of fragile x syndrome
ES2938546T3 (es)	2017-08-14	2023-04-12	Prilenia Neurotherapeutics Ltd	Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
CN111278431A (zh)	2017-08-30	2020-06-12	普瑞尼亚神经治疗有限公司	普利多匹定的高浓度剂型
CN111343982A (zh)	2017-09-08	2020-06-26	普瑞尼亚神经治疗有限公司	用于治疗药物诱发的异动症的普利多匹定
US12036213B2 (en)	2017-09-08	2024-07-16	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating drug induced dyskinesias
CN113365551A (zh) *	2019-01-31	2021-09-07	豪夫迈·罗氏有限公司	评估亨廷顿氏病的进展
CA3125893C (en)	2019-02-04	2024-03-19	Prilenia Neurotherapeutics Ltd.	Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
BR112021024744A2 (pt) *	2019-06-12	2022-03-22	Prilenia Neurotherapeutics Ltd	Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
JP7432711B2 (ja) *	2019-09-17	2024-02-16	エフ．ホフマン－ラロシュアーゲー	動作障害患者に対する個別化医療の改善
US20230390232A1 (en) *	2020-10-28	2023-12-07	Buck Institute For Research On Aging	N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
WO2005053703A1 (en)	2003-12-02	2005-06-16	Leslie James Sheldon	Combination therapy for dementia, depression and apathy
JP4891908B2 (ja)	2004-10-13	2012-03-07	エヌエスエービー，フィリアルアフニューロサーチスウェーデンアクチボラゲット，スヴェリエ	４−（３−メタンスルホニルフェニル）−１−ｎ−プロピルピペリジンの合成方法
EP1815857A1 (en) *	2006-02-02	2007-08-08	LEK Pharmaceuticals D.D.	A pharmaceutical composition comprising perindopril
PT2146961E (pt)	2007-04-12	2014-04-30	Ivax Int Gmbh	Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
US8669048B2 (en)	2008-06-24	2014-03-11	Parkinson's Institute	Pluripotent cell lines and methods of use thereof
US8384755B2 (en)	2009-08-26	2013-02-26	Intouch Technologies, Inc.	Portable remote presence robot
US20110206782A1 (en)	2010-02-24	2011-08-25	Auspex Pharmaceuticals, Inc.	Piperidine modulators of dopamine receptor
WO2011107583A1 (en) *	2010-03-04	2011-09-09	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en)	2010-09-03	2014-12-24	Ivax Int Gmbh	Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en)	2011-09-07	2015-04-14	IVAX International GmbH	Polymorphic form of pridopidine hydrochloride
US9012476B2 (en)	2011-12-08	2015-04-21	IVAX International GmbH	Hydrobromide salt of pridopidine
US9744155B2 (en)	2012-03-28	2017-08-29	Ixcela, Inc.	IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
NZ630560A (en)	2012-04-04	2016-11-25	Teva Pharmaceuticals Int Gmbh	Pharmaceutical compositions for combination therapy
EP2900226A4 (en)	2012-09-27	2016-03-30	Teva Pharma	COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
CA2884781A1 (en)	2012-09-27	2014-04-03	Teva Pharmaceutical Industries Ltd.	Laquinimod and pridopidine for treating neurodegenerative disorders
PE20161220A1 (es)	2014-01-22	2016-11-23	Teva Pharmaceuticals Int Gmbh	Formulaciones de pridopidina de liberacion modificada
TW201613859A (en)	2014-06-30	2016-04-16	Teva Pharma	Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en)	2014-12-22	2018-09-19	Teva Pharmaceuticals International GmbH	L-tartrate salt of pridopidine
PL3261721T3 (pl)	2015-02-25	2022-12-27	Prilenia Neurotherapeutics Ltd.	Stososowanie pridopidyny w celu poprawy pamięci
WO2016138135A1 (en)	2015-02-25	2016-09-01	Teva Pharmaceuticals International Gmbh	Sigma-1 receptor modulators for treating huntington's disease
US20170020854A1 (en)	2015-07-22	2017-01-26	Teva Pharmaceuticals International Gmbh	Pridopidine base formulations and their use
AR105434A1 (es)	2015-07-22	2017-10-04	Teva Pharmaceuticals Int Gmbh	Proceso para preparar pridopidina
WO2017048457A1 (en)	2015-09-18	2017-03-23	Teva Pharmaceuticals Industries Ltd.	Combination of laquinimod and pridopidine to treat multiple sclerosis
PT3504187T (pt) *	2016-08-24	2025-05-09	Prilenia Neurotherapeutics Ltd	Utilização da pridopidina no tratamento do declínio funcional
DK3503890T3 (da)	2016-08-24	2025-01-27	Prilenia Neurotherapeutics Ltd	Anvendelse af pridopidin til behandling af dystonier
CN109952100A (zh)	2016-09-15	2019-06-28	普瑞尼亚医疗发展有限公司	普利多匹定用于治疗焦虑和抑郁的用途
WO2018053275A1 (en)	2016-09-16	2018-03-22	Teva Pharmaceuticals International Gmbh	Use of pridopidine for the treatment of familial dysautonomia
PL3512506T3 (pl)	2016-09-16	2022-05-30	Prilenia Neurotherapeutics Ltd.	Zastosowanie pridopidyny w leczeniu zespołu retta

2014
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown

Also Published As

Publication number	Publication date
EP3010506B1 (en)	2021-05-12
PE20160195A1 (es)	2016-05-14
PE20170302A1 (es)	2017-03-31
EP3010506A1 (en)	2016-04-27
EP3010506A4 (en)	2017-02-08
JP2016523862A (ja)	2016-08-12
CA2913781A1 (en)	2014-12-24
KR102316933B1 (ko)	2021-10-26
KR20160055122A (ko)	2016-05-17
SG11201509729YA (en)	2015-12-30
MX2015017307A (es)	2016-08-03
CN105592848A (zh)	2016-05-18
HUE054783T2 (hu)	2021-09-28
TW201529069A (zh)	2015-08-01
BR112015029918A2 (pt)	2017-07-25
WO2014205229A8 (en)	2015-04-09
US10322119B2 (en)	2019-06-18
AU2014281414A1 (en)	2016-01-21
DK3010506T3 (da)	2021-07-12
UY35624A (es)	2015-01-30
HK1221646A1 (zh)	2017-06-09
US20140378508A1 (en)	2014-12-25
ES2879631T3 (es)	2021-11-22
EA201690069A1 (ru)	2016-06-30
CA2913781C (en)	2022-05-10
WO2014205229A1 (en)	2014-12-24
CL2015003690A1 (es)	2016-10-28
UA122999C2 (uk)	2021-02-03
IL242804B (en)	2022-02-01
MX384234B (es)	2025-03-14
PH12015502691A1 (en)	2016-03-14

Publication	Publication Date	Title
PL3010506T3 (pl)	2021-11-02	Pridopidyna w leczeniu choroby huntingtona
EP3068905A4 (en)	2017-07-05	Methods and compositions for treating huntington's disease
ZA201406209B (en)	2016-01-27	Methods and compositions for treating huntington's disease
PL2945642T3 (pl)	2024-07-29	Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom
EP3086846A4 (en)	2017-09-06	Diagnosing and treating alzheimer's disease
PL3041831T3 (pl)	2021-07-19	Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
GB201310203D0 (en)	2013-07-24	Materials and methods relating to Alzheimer's disease
EP2980096A4 (en)	2016-11-16	2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof
GB201214450D0 (en)	2012-09-26	Huntington's disease
AU353890S (en)	2014-02-25	Men's clothing
ZA201407032B (en)	2015-06-24	Preventing or treating periodontal disease
GB201309694D0 (en)	2013-07-17	Artist's implement
GB201310607D0 (en)	2013-07-31	B'jamas
GB201310101D0 (en)	2013-07-24	Treatment of freidreich's ataxia
AU350798S (en)	2013-09-12	Alu' sling sunlounger
GB201301407D0 (en)	2013-03-13	17 Deemed-Ties Blackjack
GB201309270D0 (en)	2013-07-10	Line-out Rugby aid 'Get Up's'
GB201322568D0 (en)	2014-02-05	Taggstar 1
BR302013005287S1 (pt)	2015-01-20	Configuração introduzida em calçado feminino
GB201310407D0 (en)	2013-08-07	Plantladders 3
GB201310285D0 (en)	2013-07-24	Twist-Away 270
GB201304148D0 (en)	2013-04-24	Improvements in or relating to treatment apparatus
GB201311532D0 (en)	2013-08-14	Concept 47
GB201311469D0 (en)	2013-08-14	Concept 12 12
GB201311538D0 (en)	2013-08-14	Concept 21